申请人:Howard R. Harry
公开号:US20050245543A1
公开(公告)日:2005-11-03
This invention is directed to a compound of the formula I
as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.
本发明涉及根据本文所定义的式I的化合物,或其药学上可接受的盐;含有式I化合物的药物组合物;一种治疗可能通过拮抗组胺H3受体而治疗的疾病或症状的方法,该方法包括向需要这种治疗的哺乳动物施用上述式I化合物;以及一种治疗选自抑郁症、情绪障碍、精神分裂症、焦虑症、阿尔茨海默病、注意力缺陷障碍(ADD)、注意力缺陷多动障碍(ADHD)、精神障碍、睡眠障碍、肥胖、眩晕、癫痫、晕动病、呼吸道疾病、过敏、过敏引起的气道反应、过敏性鼻炎、鼻塞、过敏性充血、充血、低血压、心血管疾病、胃肠道疾病、胃肠道高低蠕动和酸性分泌的疾病或症状的方法,该方法包括向需要这种治疗的哺乳动物施用上述式I化合物。